Karyopharm Therapeutics Inc. (KPTI) Analysts See $-0.58 EPS; Taro Pharmaceutical Industries L (TARO) Sellers Increased By 7.49% Their Shorts

February 15, 2018 - By Richard Conner

Taro Pharmaceutical Industries L (NYSE:TARO) had an increase of 7.49% in short interest. TARO’s SI was 1.50M shares in February as released by FINRA. Its up 7.49% from 1.40M shares previously. With 335,100 avg volume, 5 days are for Taro Pharmaceutical Industries L (NYSE:TARO)’s short sellers to cover TARO’s short positions. The SI to Taro Pharmaceutical Industries L’s float is 13.05%. The stock increased 4.17% or $4 during the last trading session, reaching $99.91. About 78,558 shares traded. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 13.84% since February 15, 2017 and is downtrending. It has underperformed by 30.54% the S&P500.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.58 EPS on March, 15.They anticipate $0.07 EPS change or 10.77% from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -10.77% EPS growth. The stock increased 2.19% or $0.31 during the last trading session, reaching $14.48. About 573,471 shares traded or 180.25% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 15, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company has market cap of $4.01 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It has a 19.4 P/E ratio. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $717.24 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Since August 29, 2017, it had 0 buys, and 17 sales for $1.27 million activity. Another trade for 2,195 shares valued at $21,950 was made by Primiano Christopher Brett on Tuesday, August 29. $31,702 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Mirza Mansoor Raza. Kauffman Michael sold $125,048 worth of stock. Another trade for 10,000 shares valued at $125,048 was sold by Shacham Sharon.

Investors sentiment increased to 2.5 in Q3 2017. Its up 0.94, from 1.56 in 2017Q2. It increased, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. Wells Fargo And Mn holds 26,072 shares or 0% of its portfolio. International Group Inc Inc Inc owns 22,659 shares. 24,600 were reported by Jacobs Levy Equity Inc. Fmr has invested 0.01% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Nationwide Fund Advsr reported 105,664 shares. Metropolitan Life Insur stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). 416,232 were accumulated by Northern Trust Corporation. Goldman Sachs has 80,747 shares for 0% of their portfolio. Swiss Natl Bank holds 56,850 shares or 0% of its portfolio. State Common Retirement Fund reported 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Switzerland-based Credit Suisse Ag has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). California State Teachers Retirement reported 54,693 shares stake. C Group Holdg A S holds 0% or 18,515 shares in its portfolio. Opus Point Prtn Limited Liability has invested 0.99% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Wellington Mngmt Ltd Liability Partnership has invested 0.02% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The company was downgraded on Wednesday, January 6 by Jefferies. As per Tuesday, March 15, the company rating was maintained by Jefferies. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by H.C. Wainwright on Tuesday, December 12. The firm has “Outperform” rating given on Friday, May 27 by Raymond James. JP Morgan initiated Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday, September 2 with “Overweight” rating. Bank of America downgraded Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Tuesday, March 15. Bank of America has “Underperform” rating and $11 target. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Outperform” rating given on Tuesday, June 28 by Robert W. Baird. As per Wednesday, September 9, the company rating was initiated by Jefferies. On Thursday, November 2 the stock rating was maintained by RBC Capital Markets with “Buy”.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>